Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 5/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 3/20 | 0.30 |
| ▸ | CES2 | O00748 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL777742 | 0.83 | CA1 (0.35) | CA1CA2CA9 | |
| SCHEMBL11897704 | 0.80 | CES1 (0.44) | CES1FAAHCES2 | |
| SCHEMBL6853106 | 0.80 | CA1 (0.33) | CA1CA2CA9 | |
| SCHEMBL7051925 | 0.79 | — | — | |
| SCHEMBL254306 | 0.78 | CA1 (0.32) | CES1CA1CA2CA9 | |
| SCHEMBL778116 | 0.77 | CES1 (0.36) | CES1 | |
| SCHEMBL11898016 | 0.76 | CES1 (0.55) | CES1CA2FAAHCES2 | |
| SCHEMBL7051921 | 0.75 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL776907 | 0.75 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL12140036 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024114190-A1 | ELECTROLYTE COMPOSITION, METHOD FOR SECONDARY ELECTROLYTE FILLING, AND LITHIUM SECONDARY BATTERY | 九江天赐高新材料有限公司 | 2024-06-06 | — | — | WO | claimed |
| CN-115594670-A | Trifluoromethyl containing oxadiazole derivatives, preparation method and application thereof | 浙江省化工研究院有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-115458808-B | Method for producing lithium fluorosulfonate, nonaqueous electrolyte solution, and nonaqueous electrolyte secondary battery | 三菱化学株式会社 | 2026-05-15 | — | — | CN | disclosed |
| US-12620622-B2 | Compound including sulfur-containing heterocyclic cation and bis(oxolato)borate anion, electrolytic solution and electrochemical device including the same | DAIKIN INDUSTRIES, LTD. (JP) | 2026-05-05 | — | — | US | disclosed |
| US-20260081225-A1 | ELECTROLYTIC SOLUTION AND BATTERY | Guangzhou Tinci Materials Technology Co., Ltd (CN) | 2026-03-19 | — | — | US | disclosed |
| EP-4704208-A1 | ELECTROLYTE AND BATTERY | Guangzhou Tinci Materials Technology Co., Ltd (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-12494506-B2 | Nonaqueous electrolytic solution and energy device including the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-12-09 | — | — | US | disclosed |
| US-12456760-B2 | Non-aqueous electrolyte solution for sodium ion secondary battery, and sodium ion secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-10-28 | — | — | US | disclosed |
| US-20250266502-A1 | LITHIUM-ION BATTERY ELECTROLYTIC SOLUTION, LITHIUM-ION BATTERY, AND METHOD FOR IMPROVING BATTERY PERFORMANCE | Guangzhou Tinci Materials Technology Co., Ltd (CN) | 2025-08-21 | — | — | US | disclosed |
| US-20250260063-A1 | ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, SECONDARY BATTERY, AND LITHIUM-ION SECONDARY BATTERY | DAIKIN INDUSTRIES, LTD. (JP) | 2025-08-14 | — | — | US | disclosed |
| EP-3780232-B1 | ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY BATTERY, AND MODULE | DAIKIN IND LTD (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-20110206783-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-7750151-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| EP-1730110-B1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280899-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-20070042968-A1 | Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260081225-A1 | ELECTROLYTIC SOLUTION AND BATTERY | HCN1, HCN2, HCN3 | CES1 2875/4885CA1 120/4885CA2 46/4885 |
| US-20080280899-A1 | Inhibitors of Akt Activity | AKT1, AKT2, AKT3 | CES1 2255/4885CA1 1894/4885CA2 2592/4885 |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | CES1 3352/4885CA1 905/4885CA2 3392/4885 |
| US-20110206783-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | CES1 3405/4885CA1 3905/4885CA2 1650/4885 |
| US-12620622-B2 | Compound including sulfur-containing heterocyclic cation and bis(oxolato)borate anion, electrolytic solution and electrochemical device including the same | ASH2L, OLA1, ODC1 | CES1 2196/4885CA1 167/4885CA2 32/4885 |
| US-12456760-B2 | Non-aqueous electrolyte solution for sodium ion secondary battery, and sodium ion secondary battery | NHERF1, NAP1L1, NAF1 | CES1 2113/4885CA1 68/4885CA2 150/4885 |
| US-20070042968-A1 | Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease | PRSS1, PRSS3, HPN | CES1 317/4885CA1 2186/4885CA2 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.